Adil Daud
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 179
- Cancer Immunotherapy and Biomarkers 100
- CAR-T cell therapy research 69
- Cutaneous Melanoma Detection and Management 23
- Colorectal Cancer Treatments and Studies 16
-
- Melanoma and MAPK Pathways 77
- Histone Deacetylase Inhibitors Research 15
- Co-authors
- Omid Hamid (63 shared papers)Pamela N. Münster (38 shared papers)Antoni Ribas (51 shared papers)Caroline Robert (43 shared papers)Daniel M. Sullivan (16 shared papers)Alain P. Algazi (48 shared papers)Katy K. Tsai (34 shared papers)Nageatte Ibrahim (16 shared papers)
- Journals
- Journal of Clinical Oncology (107 papers)Annals of Oncology (17 papers)Clinical Cancer Research (12 papers)European Journal of Cancer (10 papers)Cancer Research (9 papers)
- Partner nations
- United StatesAustraliaFrance
In The Last Decade
Adil Daud
278 papers receiving 15.9k citations
Adil Daud's Hit Papers
Peers
Comparison fields: 5 of 135
- Oncology 8.8k
- Immunology 4.5k
- Molecular Biology 6.5k
- Biotechnology 725
- Cancer Research 1.0k
Countries citing papers authored by Adil Daud
This map shows the geographic impact of Adil Daud's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adil Daud with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adil Daud more than expected).
Fields of papers citing papers by Adil Daud
This network shows the impact of papers produced by Adil Daud. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adil Daud. The network helps show where Adil Daud may publish in the future.
Co-authors
The 25 scholars most cited alongside Adil Daud, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 293 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Hit paper breakdown → | 2017 | 911 |
| 2 | Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity Hit paper breakdown → | 2014 | 904 |
| 3 | Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Hit paper breakdown → | 2019 | 788 |
| 4 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Hit paper breakdown → | 2019 | 651 |
| 5 | Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma Hit paper breakdown → | 2008 | 511 |
| 6 | Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity Hit paper breakdown → | 2019 | 451 |
| 7 | Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma Hit paper breakdown → | 2009 | 417 |
| 8 | 2008 | 414 | |
| 9 | Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma Hit paper breakdown → | 2016 | 388 |
| 10 | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer Hit paper breakdown → | 2015 | 383 |
| 11 | A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. | 2002 | 371 |
| 12 | Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression Hit paper breakdown → | 2015 | 362 |
| 13 | 2002 | 355 | |
| 14 | 2017 | 338 | |
| 15 | Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodies Hit paper breakdown → | 2016 | 269 |
| 16 | 2020 | 212 | |
| 17 | 2008 | 208 | |
| 18 | 2014 | 203 | |
| 19 | 2013 | 190 | |
| 20 | 2007 | 185 |
About Adil Daud
Adil Daud is a scholar working on Oncology, Molecular Biology, Immunology, Organic Chemistry and Biotechnology, having authored 293 papers that have together received 16.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (100 papers), Melanoma and MAPK Pathways (77 papers), CAR-T cell therapy research (69 papers), Immunotherapy and Immune Responses (47 papers), Cutaneous Melanoma Detection and Management (23 papers), Colorectal Cancer Treatments and Studies (16 papers), Histone Deacetylase Inhibitors Research (15 papers) and Microbial Inactivation Methods (14 papers). The work is most often cited by research in Oncology (8.8k citations), Immunology (4.5k citations), Molecular Biology (6.5k citations), Biotechnology (725 citations) and Cancer Research (1.0k citations). Adil Daud has collaborated with scholars based in United States, Australia and France. Frequent co-authors include Omid Hamid, Pamela N. Münster, Antoni Ribas, Caroline Robert, Daniel M. Sullivan, Alain P. Algazi, Katy K. Tsai, Nageatte Ibrahim, Douglas C. Marchion and Jeffrey S. Weber. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, European Journal of Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.